Betterchem
Health     Drug Information     DMFs     Portal     21CFR     Search     Site Map

 
ALENDRONATE
Our exclusive Federal Register search…


 

This API's Main News Page.
 

                                                                   
 

FDA Approval Activities for this Drug…

Alendronate Sodium Tablets, 35 & 70 mg, Barr, ANDA 76-184 4/23/02 Alendronate Sodium Tablets, 5, 10 & 40 mg, Ivax ANDA 75-711 7/24/02 Alendronate Sodium Tablets, 5, 10, 35, 40 & 70 mg (base), Teva ANDA 75-710 Fosamax (alendronate sodium) Solution, Merck NDA 21-575 9/17/03 9/25/03 9/25/03 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-037 3/24/03 3/26/03 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-036 8/5/02 8/12/02 8/5/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-033 8/13/02 8/14/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-031 7/25/02 7/26/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-028 9/16/02 9/20/02 9/17/02 Fosamax Tablets,10mg, Merck Research NDA 20-560/S-012 6/16/99 6/17/99 6/17/99 6/19/00 Fosamax Indication: for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Fosamax Tablets, 5mg, 10mg & 40 mg, Merck Research NDA 20-560/S-013 6/8/99 6/19/00 Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-018 11/24/99 12/29/99 4/24/03 Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-015 11/24/99 12/29/99 4/24/03 Fosamax (alendronate sodium) Tablets,35 & 70mg, Merck Research NDA 20-560/S-021 & S-22 10/20/00 10/30/00 8/16/01 Fosamax Indication: for the prevention (S-021) and treatment (S-022) of postmenopausal osteoporosis, respectively. Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-023 9/29/00 10/10/00 Fosamax Indication: Treatment to increase bone mass in men with osteoporosis. Fosamax (alendronate sodium) Tablets,70mg, Merck & Co., NDA 20-560/S-024 & S-025 1/31/01 2/8/01 2/8/01 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S40 9/17/03 9/29/03 Fosamax Indication: Treatment to increase bone mass in men with osteoporosis. Alendronate Sodium Tablets, Mylan Pharmaceuticals, Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Alendronate Sodium Tablets, Watson Laboratories | Fosamax Plus D (alendronate sodium vitamin D3) Tablets, Merck & Co., Approval

For the most up-to-date approval information, please locate this API using the drug index. For industry specific content, please visit USActives.com.


 

Other APIs… A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z

Find API by Brand Name | Health | DMF Index | 21 CFR | Federal Register | Home Page | Site Map

 

 

 

© 2012 Betterchem.com